$STX

MOSLEY WILLIAM D sold $411K of STX

MOSLEY WILLIAM D (CEO) sold 440 shares of Seagate Technology Holdings plc (STX) at $934.17 ($0.41M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MOSLEY WILLIAM D
Published Jun 2, 2026, 9:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STX
Neutral
medium confidence
Mentioned
$STX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STXNeutralLow
01

Why it matters

The disclosure updates the insider activity record but does not introduce a new company-specific fundamental catalyst (no earnings, guidance, litigation, or deal).

02

Market read

Traders may monitor for follow-on insider activity, but this specific filing is unlikely to drive a sustained repricing without additional news.

03

What to watch

The article doesn’t show whether this sale is part of a larger, recurring pattern or whether other insiders/major holders are buying/selling concurrently.

Relevance 6/10Novelty 6/10Timing: Filed June 2; transaction dated June 1 (10b5-1 sale disclosed after the fact).

Background

SEC Form 4 insider transaction: CEO William D. Mosley sold STX shares (open-market) under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$STXNeutralMedium confidence
Context

Seagate CEO William D. Mosley sold 440 shares in an open-market transaction under a pre-arranged 10b5-1 plan on June 1.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and outweighed by broader fundamentals.

Evidence & confidence

The filing is a routine insider transaction with a stated 10b5-1 plan, and the article provides no accompanying operational/financial catalyst.

Market effects

Limited read-through to the storage/Seagate peer group because this is a single-company insider sale without new fundamentals.

None specific; disclosure is US-listed and not tied to a regional operational event.

None specific; no guidance, deal, or regulatory development mentioned.

Counterpoint

A 10b5-1 sale can still coincide with internal confidence in liquidity planning rather than bearish expectations; the market may overreact to the headline.

Key entities

  • Seagate Technology Holdings plc

    STX insider transaction disclosed on SEC Form 4; CEO sold shares under a 10b5-1 plan.

  • William D. Mosley

    CEO and officer/director who executed the reported sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVDAHighAI 9/10

Markets News, Aug. 27, 2026: Nvidia Stock Powers Higher After Earnings, Driving Tech Gains; Nasdaq Closes Sharply Higher

Nvidia (NVDA) reported strong Q2 earnings and raised Q3 revenue guidance to $108B, driving its stock up 9% and boosting tech sector gains. Nasdaq, S&P 500, and Dow closed higher. Other notable movers include Okta (OKTA) +29%, Salesforce (CRM) +23%, and CrowdStrike (CRWD) +20%. Corporate profits surged $400B in Q2, partly due to $71B in tariff refunds.

$STXMed

Moody’s upgrades Seagate Data rating on AI demand strength

Moody's upgraded Seagate Data's corporate family rating to Ba1 from Ba2, citing AI-driven demand for high-capacity HDDs. The agency expects revenues to grow over 30% annually, reaching $20B, and debt to EBITDA to fall below 0.5x. Seagate faces risks from revenue concentration and pricing pressures. The company had $1.7B in cash and access to a $1.3B credit facility as of July 2026.

$MRNAHighAI 8/10

3 Stocks Soared, 3 Stocks Slumped

Moderna (MRNA) surged 176.97% to $174.38 after reporting positive trial results for a cancer therapy with Merck (MRK). Estee Lauder (EL) rose 16% to $98.01 with revenue up 6.5% Y/Y. MicroStrategy (MSTR) gained 12.68% as Bitcoin prices rose. Nebius (NBIS) fell 10% after a $4.5B convertible note offering. Seagate (STX) dropped 8% to $832.56.

$STXMed

REG - Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US

Shield Therapeutics (STX) will take full control of ACCRUFeR® in the US from Viatris by September 30, 2026. The deal is expected to boost Shield's profitability and growth, with no upfront payments to Viatris. Shield will pay royalties on US net sales, ranging from high single digits to mid-teens over five years, and retain all gross profits from US sales. The transaction is anticipated to enhance Shield's financial profile and support its path to sustained profitability.